HealthDay News – Incretin-based drugs are not associated with increased risk of hospitalization for heart failure, according to a study published in the March 24 issue of the New England Journal of Medicine.
Kristian B. Filion, PhD, from the Jewish General Hospital in Montreal, Canada and colleagues used health care data from 4 Canadian provinces, the United States, and the United Kingdom to examine the risk of heart failure associated with antidiabetic incretin-based drugs. Each patient who was hospitalized for heart failure was matched with up to 20 controls from the same cohort in a nested case-control analysis. Data were included for 1 499 650 patients, with 29 741 hospitalized for heart failure.
Researchers observed no increase in the rate of hospitalization for heart failure with the use of incretin-based drugs vs oral antidiabetic-drug combinations among patients with a history of heart failure (hazard ratio [HR]: 0.86; 95% confidence interval [CI], 0.62-1.19), or among those without heart failure history (HR: 0.82; 95% CI: 0.67-1.00). Similar results were seen for dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 analogs.
“In this analysis of data from large cohorts of patients with diabetes, incretin-based drugs were not associated with an increased risk of hospitalization for heart failure, as compared with commonly used combinations of oral antidiabetic drugs,” the authors wrote.
Filion KB, Azoulay L, Platt RW, et al; for the CNODES Investigators. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374:1145-1154. doi: 10.1056/NEJMoa1506115.